|
1000
|
Abstract/Summary
|
-
<jats:title>Abstract</jats:title><jats:p>Drugs with multiple targets, often annotated as ‘unselective’, ‘promiscuous’, ‘multitarget’, or ‘polypharmacological’, are widely considered in both academic and industrial research as a high risk due to the likelihood of adverse effects. However, retrospective analyses have shown that particularly approved drugs bear rich polypharmacological profiles. This raises the question whether our perception of the specificity paradigm (‘one drug-one target concept’) is correct – and if specifically multitarget drugs should be developed instead of being rejected. These questions provoke a paradigm shift – regarding the development of polypharmacological drugs not as a ‘waste of investment’, but acknowledging the existence of a ‘lack of investment’. This perspective provides an insight into modern drug development highlighting latest drug candidates that have not been assessed in a broader polypharmacology-based context elsewhere embedded in a historic framework of classical and modern approved multitarget drugs. The article shall be an inspiration to the scientific community to re-consider current standards, and more, to evolve to a better understanding of polypharmacology from a challenge to an opportunity.</jats:p>
|
|
1000
|
Hinweis
|
-
DeepGreen-ID: 81df9a6321e34b94bb9b50d7ddb70198 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
|
